<DOC>
	<DOCNO>NCT02849210</DOCNO>
	<brief_summary>The study design accord draft allergenic product regulation publish Spanish Regulatory Agency . The aim study evaluate safety tolerability subcutaneous immunotherapy Olea europaea pollen extract patient rhinoconjunctivitis without associate mild asthma . In addition , surrogate efficacy parameter evaluate : immunoglobulin level change skin reactivity</brief_summary>
	<brief_title>A Clinical Trial With Subcutaneous Immunotherapy Depot Presentation Patients With Rhinoconjuncitivis Sensitized Olea Europaea</brief_title>
	<detailed_description>An study conduct througout Spain 4000 allergic patient ( Alergoloógica 2005 ) show 47 % patient rhinoconjuncitivits 51 % asthmatic patient sentitized olive pollen . This give u idea importance allergen sensitization Spain .</detailed_description>
	<criteria>1 . Patients must sign informed consent form . 2 . Patients must 18 60 year age . 3 . Patients seasonal allergic rhinoconjunctivitis Olea europea minimum 2 year prior study participation . Although allergic rhinoconjunctivitis pathology study , inclusion patient mild concomitant asthma allow . 4 . Patients obtain prick test result ≥ 3 mm diameter Olea europaea Positive negative control test give consistent result . 5 . Patients specific immunoglobulin E ≥ class 2 ( CAP/PHADIA ) Olea europaea . 6 . Patients sensitize Olea europaea clinically relevant symptom treatment Olea europea 100 % vaccine indicate . 7 . Patients meet windows treatment describe protocol , treatment study procedure . 8 . Women childbearing potential must negative urine pregnancy test Screening visit/Visit 0 . 9 . Women childbearing potential must agree use appropriate contraception method study sexually active . 1 . Patients receive immunotherapy previous 5 year Olea europaea allergen cross reactivity patient currently receive immunotherapy allergen . 2 . Patients severe asthma forzed expiratoy volumen 1 second FEV1 &lt; 70 % even pharmacologically control . 3 . Patients : immunological , cardiac , renal hepatic illness medical condition investigator deem relevant interfere study . 4 . Polisensitized patient inhalant allergen besides Olea europaea , judgment investigator may present symptom clinically relevant airborne allergen participate study 5 . Patients previous history anaphylaxis 6 . Patients chronic urticaria , 7 . Patients moderate severe atopic dermatitis 8 . Patients participate another clinical trial within 3 month prior enrolment . 9 . Patients treatment tricyclic antidepressives , phenothiazine , βblockers , Angiotensin Converting Enzyme Inhibitors ( ACEI ) 10 . Female patient pregnant breastfeed 11 . Patient attend visit 12 . Patient 's lack collaboration refusal participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>